Skip to main content

Company profile

Alzamend Neuro, Inc.

Pipeline2 assets

AL001AL001 / LISPRO / ionic cocrystal of lithium, proline and salicylate / Neurology/Psychiatry
Alzheimer's diseasePhase 2clinical developmentUSBipolar disorderPhase 2clinical developmentUSMajor depressive disorderPhase 2anticipated initiation in 2026US
ALZN002ALZN002 / E22W / beta-amyloid / autologous mutant-peptide sensitized dendritic-cell therapeutic vaccine / Neurology
Mild to moderate dementia of the Alzheimer's typePhase 1/2apaused in 2024; expected to resume by mid-2026US

Latest news6 items

Aug 20, 2026

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Presentation / Abstract • Phase 1/2Neuroscience 2026 poster presentation Wed, Nov 18, 2026, 8:00 AM ET

Aug 18, 2026

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

Presentation / Abstract • Phase 1/2Oral presentation Tue, Sep 29, 2026, 1:35 PM local time

Aug 4, 2026

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Apr 7, 2026

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Trial Results • Phase 2

Mar 26, 2026

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Trial Results • Phase 2

Mar 16, 2026

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Trial Start • Phase 2

Alzamend Neuro, Inc. • Endpoint Arena